Ottó Lehoczky

Summary

Country: Hungary

Publications

  1. ncbi request reprint [Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet Nogyógyászati Osztály, Budapest
    Orv Hetil 148:2337-42. 2007
  2. ncbi request reprint [Review of effectiveness of chemotherapy with gemcitabine in ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály
    Orv Hetil 146:2351-7. 2005
  3. ncbi request reprint [Neoadjuvant chemotherapy in the treatment of ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály osztályvezeto foorvos Pulay Tamás
    Orv Hetil 146:1951-5. 2005
  4. ncbi request reprint [Survival reflecting the effectiveness of primary operation in patients with epithelial ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály, Budapest
    Orv Hetil 148:929-33. 2007
  5. ncbi request reprint [Results of docetaxel therapy in patients with relapsed ovarian cancer]
    Ottó Lehoczky
    Nogyógyászati Osztály, Országos Onkológiai Intézet, 1122 Budapest, Ráth György u 7 9, Hungary
    Magy Onkol 49:71-5. 2005
  6. ncbi request reprint [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy]
    Ottó Lehoczky
    Országos Onkológiai Intézet Nogyógyászati Osztálya Budapest
    Orv Hetil 148:2081-5. 2007
  7. ncbi request reprint Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients--a randomized study
    Ottó Lehoczky
    Gynecologic Oncology Department, National Institute of Oncology, Rath Gy u 7 9, H 1122 Budapest, Hungary
    Eur J Obstet Gynecol Reprod Biol 113:94-7. 2004
  8. ncbi request reprint [Frequency of anemia in patients with ovarian cancer: assessment of our own data in connection with the European Cancer Anemia Survey (ECAS)]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály, Budapest
    Orv Hetil 144:2225-8. 2003
  9. ncbi request reprint [Metastatic breast cancer in the uterine cervix: two cases of a rare occurrence]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nógyógyászati Onkológiai Osztálya, Budapest
    Orv Hetil 144:1637-8. 2003
  10. ncbi request reprint [Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nógyógyászati Osztálya, Budapest
    Orv Hetil 144:1381-4. 2003

Detail Information

Publications25

  1. ncbi request reprint [Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet Nogyógyászati Osztály, Budapest
    Orv Hetil 148:2337-42. 2007
    ..Second-line chemotherapies result in a progression-free interval of 2,3-42 months...
  2. ncbi request reprint [Review of effectiveness of chemotherapy with gemcitabine in ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály
    Orv Hetil 146:2351-7. 2005
    ..The first publications on this treatment form are promising, however, a final policy in this matter can only be assumed after finishing the evaluation of the comprehensive, randomised studies (GOG-0182-ICON5) in progress...
  3. ncbi request reprint [Neoadjuvant chemotherapy in the treatment of ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály osztályvezeto foorvos Pulay Tamás
    Orv Hetil 146:1951-5. 2005
    ..However, neoadjuvant chemotherapy remain as an alternative treatment for patients with ovarian cancer of advanced stage and poor internal status, for whom there is no other choice for tumor elimination...
  4. ncbi request reprint [Survival reflecting the effectiveness of primary operation in patients with epithelial ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály, Budapest
    Orv Hetil 148:929-33. 2007
    ..The optimal result is more frequent in operations performed by gynecologist oncologists as is in surgery administered by general gynecologists or general surgeons...
  5. ncbi request reprint [Results of docetaxel therapy in patients with relapsed ovarian cancer]
    Ottó Lehoczky
    Nogyógyászati Osztály, Országos Onkológiai Intézet, 1122 Budapest, Ráth György u 7 9, Hungary
    Magy Onkol 49:71-5. 2005
    ..In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers...
  6. ncbi request reprint [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy]
    Ottó Lehoczky
    Országos Onkológiai Intézet Nogyógyászati Osztálya Budapest
    Orv Hetil 148:2081-5. 2007
    ..Thrombotic events are infrequently observed in erythropoietin treatments for the anemia in tumorous patients with chemotherapy. The manufacturers call attention to this possible side effect of all kind of such drugs...
  7. ncbi request reprint Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients--a randomized study
    Ottó Lehoczky
    Gynecologic Oncology Department, National Institute of Oncology, Rath Gy u 7 9, H 1122 Budapest, Hungary
    Eur J Obstet Gynecol Reprod Biol 113:94-7. 2004
    ..The authors administered two doses of oral methylprednisolone in combination with 3mg granisetron intravenously for the prophylaxis of cisplatin-induced emesis in gynecologic cancer patients...
  8. ncbi request reprint [Frequency of anemia in patients with ovarian cancer: assessment of our own data in connection with the European Cancer Anemia Survey (ECAS)]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nogyógyászati Osztály, Budapest
    Orv Hetil 144:2225-8. 2003
    ..9%, 1.1%, p = 0.8572). Data of the authors underline the importance of prophylaxis and treatment of anemia in chemotherapy courses of ovarian cancer patients...
  9. ncbi request reprint [Metastatic breast cancer in the uterine cervix: two cases of a rare occurrence]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nógyógyászati Onkológiai Osztálya, Budapest
    Orv Hetil 144:1637-8. 2003
    ..The final diagnoses was proved by cervical conisation in the first patient and by hysterectomy in the second one. Authors call attention for the possibility of the rare site of symptom free recurrence...
  10. ncbi request reprint [Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nógyógyászati Osztálya, Budapest
    Orv Hetil 144:1381-4. 2003
    ..Paclitaxel-carboplatin combination chemotherapy has been administered worldwide in the first-line adjuvant treatment of epithelial ovarian cancers since the mid 1990's...
  11. ncbi request reprint [Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?]
    O Lehoczky
    Nógyógyászati Onkológiai Osztály, Országos Onkológiai Intézet, Budapest
    Orv Hetil 142:1681-4. 2001
    ..Authors conclude the addition of an anxiolytic drug does not improve the antiemetic effectivity of the granisetron-methylprednisolone combination in the first 24 hours of cisplatin chemotherapy...
  12. ncbi request reprint [Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet Nogyógyászati Osztálya, Budapest
    Orv Hetil 148:2133-7. 2007
    ..According to this document the blood transfusions are indicated at the level of 9 g/dL of hemoglobin. Up to this year a definitive limit for applying blood transfusion in chemotherapy-induced anemia has not been determined in Hungary...
  13. ncbi request reprint [Early results of topotecan therapy in patients with recurrent ovarian cancer]
    Ottó Lehoczky
    Nógyógyászati Onkológiai Osztály, Országos Onkológiai Intézet, Budapest
    Orv Hetil 143:825-8. 2002
    ..Topotecan inhibits the topoisomerase-I enzyme resulting its stabilisation on the DNA and the suspension of replication and transcription...
  14. ncbi request reprint Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients
    O Lehoczky
    Gynecologic Oncology Department, National Institute of Oncology, Budapest, Hungary
    Neoplasma 49:126-8. 2002
    ..75% complete response and 11% major response rates were found. Authors conclude that fast dissolving ondansetron is a new and effective preparation that enriches the panel of available supporting drugs...
  15. ncbi request reprint [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nógyógyászati Onkológiai Osztálya, Budapest
    Orv Hetil 143:2189-91. 2002
    ..Hypersensitive reaction is its most serious side effect including hypotension, respiratory distress, extensive urticaria or an intense cardiotoxicity. Due to these signs several physicians abandon of the otherwise hopeful chemotherapy...
  16. ncbi request reprint Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients
    O Lehoczky
    Gynecological Oncology Department, National Institute of Oncology, Budapest, XII, Rath Gy u 7 9, Hungary, H 1122
    J Obstet Gynaecol 22:312-3. 2002
  17. ncbi request reprint Transverse leukonychia secondary to paclitaxel-carboplatin chemotherapy in a patient with ovarian cancer
    O Lehoczky
    Gynecological Oncology Department, National Institute of Oncology, Budapest, Hungary
    J Obstet Gynaecol 22:694. 2002
  18. ncbi request reprint [Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet Nogyógyászati Osztály, Budapest
    Orv Hetil 147:1405-8. 2006
    ..This is the rationale for several new chemotherapy trials, however the expected results are awaited yet. The pyrimidine analogue drug gemcitabine belongs also to this group of hopeful therapies to increase the outcomes...
  19. ncbi request reprint [Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin]
    Ottó Lehoczky
    Nogyógyászati Osztály, Országos Onkológiai Intézet, Budapest, 1122
    Magy Onkol 49:315-8. 2005
    ..The authors summarize the results of paclitaxel-carboplatin therapy of the years from 2000 to 2002, and compare them to the results observed in 2002...
  20. ncbi request reprint [First observations of the dose-dense weekly docetaxel therapy in relapsed ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Budapest 1122, Hungary
    Magy Onkol 50:43-6. 2006
    ..Weekly docetaxel therapy is a new therapeutical form of relapsed ovarian cancer. Phase I and II trials of this administration form are rare in the literature of this tumor type. The authors report on a retrospective study of this treatment...
  21. ncbi request reprint [Pure red-cell anemia due to recombinant human erythropoietin and its status in oncology practice]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Budapest 1122, Hungary
    Magy Onkol 48:163-6. 2004
    ..The side effect observed in chronic renal failure patients calls the attention to the precise compliance with the instructions of the manufacturers...
  22. ncbi request reprint [Effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Budapest, 1122, Hungary
    Magy Onkol 50:261-4. 2006
    ..The aim of this study was to evaluate toxicity profile and effectiveness of this treatment in patients with recurrent ovarian cancer...
  23. ncbi request reprint [Second-line chemotherapy with paclitaxel for ovarian cancer]
    O Lehoczky
    Nógyógyászati Onkológiai Osztály, Országos Onkológiai Intézet, Budapest
    Orv Hetil 142:2299-301. 2001
    ..These results, which are similar to the literature data have led to the agreement: paclitaxel can be applied in ovarian cancer patients only in first-line chemotherapy in Hungary from the year 2000...
  24. ncbi request reprint Recurrent giant fibroepithelial stromal polyp of the vulva associated with congenital lymphedema
    Zsolt Orosz
    Department of Oncopathology, National Institute of Oncology, Budapest, Hungary
    Gynecol Oncol 98:168-71. 2005
    ..Fibroepithelial stromal polyp is generally an easily recognizable entity, but certain cases cause differential diagnostic problems...
  25. ncbi request reprint Side-effects of paclitaxel therapy in ovarian cancer patents
    O Lehoczky
    Gynecologic Oncology Department, National Institute of Oncology, Budapest, Hungary
    Eur J Gynaecol Oncol 22:81-4. 2001
    ..One patient complained of severe neuropathy (nervus oculomotorius paresis), and another one developed severe ECG abnormalities CONCLUSIONS: When suitable premedication is applied few side-effects of PTXL therapy are reported...